Health care industry
Wells Fargo becomes bullish on this biotech company
Neurocrine Biosciences ‘ drug pipeline is turning a corner and the company will be “knocking on the doors of the large-cap club” soon, according to Wells Fargo. Analyst Mohit Bansal upgraded shares to overweight from equal weight, and raised his price target to $170 from $140, suggesting around 21% upside potential from Tuesday’s close. Bansal […]
Read More
Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected. Biogen and […]
Read More
More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says
More than 3 million people with Medicare could be eligible for coverage of Wegovy now that the blockbuster weight loss drug is also approved in the U.S. for heart health, according to an analysis released Wednesday by health policy research organization KFF. But some eligible beneficiaries could still face out-of-pocket costs for the highly popular […]
Read More
Oracle is moving its world headquarters to Nashville to be closer to health-care industry
Larry Ellison, co-founder and chairman of Oracle, speaks during the Oracle OpenWorld 2017 conference in San Francisco on Oct. 3, 2017. David Paul Morris | Bloomberg | Getty Images Oracle Chairman Larry Ellison said Tuesday that the company is moving its world headquarters to Nashville, Tennessee, to be closer to a major health-care epicenter. In […]
Read More
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn’t fully recovered just yet
Angelp | Istock | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! After a two-year dry spell, initial public offerings by biotech companies showed signs of life during the first three months of 2024. But it’s too early to say that […]
Read More
UnitedHealth paid ransom to bad actors, says patient data was compromised in Change Healthcare cyberattack
Omar Marques | Lightrocket | Getty Images UnitedHealth Group on Monday said it paid a ransom to cyber threat actors to try and protect patient data, following the February cyberattack on its subsidiary Change Healthcare. The company also confirmed that files containing personal information were compromised in the breach. “This attack was conducted by malicious threat actors, […]
Read More
Meet the private doctor to the wealthy — at $40,000 a year
Dr. Jordan Shlain, founder of Private Medical. Credit: Jordan Shlain A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. When people ask Dr. Jordan Shlain to describe his medical practice, he says […]
Read More
Most people on weight loss drugs are spending less on restaurants and takeout, survey says
A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023. Jeenah Moon | The Washington Post | Getty Images A highly popular group of weight loss and diabetes drugs is decreasing some consumers’ appetites — and also how much they spend on food. Most people taking those medications, […]
Read More
23andMe CEO Anne Wojcicki considers taking company private
Signage at 23andMe headquarters in Sunnyvale, California, U.S., on Wednesday, Jan. 27, 2021. David Paul Morris | Bloomberg | Getty Images 23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private after its stock price has tumbled more than 95% from its 2021 highs. Wojcicki is working with advisors and […]
Read More
Promise of Eli Lilly’s weight-loss drug for sleep apnea adds another reason to own the stock
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the […]
Read More